{"id":"cos-with-gnrh-antagonists-and-hp-hmg","safety":{"commonSideEffects":[{"rate":null,"effect":"Ovarian hyperstimulation syndrome (OHSS)"},{"rate":null,"effect":"Abdominal bloating and discomfort"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Mood changes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GnRH antagonists block gonadotropin-releasing hormone receptors to prevent the natural LH surge that would trigger premature ovulation during fertility treatment. Simultaneously, HP-HMG provides exogenous FSH and LH to promote controlled growth of multiple ovarian follicles. This combination allows precise timing of oocyte retrieval for in vitro fertilization or other assisted reproductive procedures.","oneSentence":"This protocol combines controlled ovarian stimulation (COS) with GnRH antagonists to suppress premature luteinizing hormone surge and HP-HMG (highly purified human menopausal gonadotropin) to stimulate multiple follicle development for assisted reproductive technology.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:29:22.931Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Infertility treatment via controlled ovarian stimulation for in vitro fertilization (IVF)"},{"name":"Assisted reproductive technology requiring multiple oocyte retrieval"}]},"trialDetails":[{"nctId":"NCT02738580","phase":"PHASE4","title":"Follicular Steroid Genesis in Controlled Ovarian Stimulation","status":"COMPLETED","sponsor":"Instituto Valenciano de Infertilidad, IVI VALENCIA","startDate":"2016-10-18","conditions":"Infertility, Controlled Ovarian Hyperstimulation","enrollment":112}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GnRH antagonists and HP-HMG"],"phase":"marketed","status":"active","brandName":"COS with GnRH antagonists and HP-HMG","genericName":"COS with GnRH antagonists and HP-HMG","companyName":"Instituto Valenciano de Infertilidad, IVI VALENCIA","companyId":"instituto-valenciano-de-infertilidad-ivi-valencia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This protocol combines controlled ovarian stimulation (COS) with GnRH antagonists to suppress premature luteinizing hormone surge and HP-HMG (highly purified human menopausal gonadotropin) to stimulate multiple follicle development for assisted reproductive technology. Used for Infertility treatment via controlled ovarian stimulation for in vitro fertilization (IVF), Assisted reproductive technology requiring multiple oocyte retrieval.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}